肺及肺外神经内分泌肿瘤中的Delta样配体3（DLL3）情况
Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms.
作者信息
Serrano Alejandra G, Rocha Pedro, Freitas Lima Cibelle, Stewart Allison, Zhang Bingnan, Diao Lixia, Fujimoto Junya, Cardnell Robert J, Lu Wei, Khan Khaja, Sable Beate, Ellison Aaron R, Wistuba Ignacio I, Concannon Kyle F, Halperin Daniel M, Bogdan Czerniak, Sircar Kanishka, Zhang Miao, Cargill Kasey, Wang Qi, Aparicio Ana, Lazar Alexander, Hernandez Sharia, Estrella Jeannelyn, Ramalingam Preetha, El-Naggar Adel, Kalhor Neda, Gay Carl M, Byers Lauren Averett, Solis Soto Luisa M
机构信息
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
NPJ Precis Oncol. 2024 Nov 19;8(1):268. doi: 10.1038/s41698-024-00739-y.
Delta-like Ligand 3 (DLL3) targeting therapies are promising in small cell lung cancer (SCLC) treatment. However, DLL3 expression in SCLC and other neuroendocrine neoplasms (NEN) is heterogeneous and not well characterized. We describe the landscape of DLL3 at the mRNA and protein levels across SCLC, large cell neuroendocrine carcinoma (LCNEC), and non-small cell lung cancer. Additionally, we explore its expression in extra-pulmonary NEN (EP-NEN) using a standardized DLL3 IHC assay. DLL3 expression is enriched in SCLC, LCNEC along with combined histology lung cancers. Moreover, we find a wide range of DLL3 expression in high-grade EP-NEN. We describe heterogenous DLL3 expression not only in SCLC but also in different NEN types. This comprehensive characterization of DLL3 can help guide future clinical trial design targeting DLL3 in NEN including LCNEC and EP-NEN that are lacking standard of care treatment options.
靶向Delta样配体3（DLL3）的疗法在小细胞肺癌（SCLC）治疗中很有前景。然而，DLL3在SCLC和其他神经内分泌肿瘤（NEN）中的表达具有异质性，且尚未得到充分表征。我们描述了DLL3在SCLC、大细胞神经内分泌癌（LCNEC）和非小细胞肺癌中的mRNA和蛋白质水平情况。此外，我们使用标准化的DLL3免疫组化检测方法探索其在肺外NEN（EP-NEN）中的表达。DLL3表达在SCLC、LCNEC以及混合组织学类型的肺癌中富集。此外，我们在高级别EP-NEN中发现了广泛的DLL3表达。我们描述了DLL3不仅在SCLC中，而且在不同类型的NEN中都存在异质性表达。对DLL3的这种全面表征有助于指导未来针对NEN（包括缺乏标准治疗方案的LCNEC和EP-NEN）中DLL3的临床试验设计。
Zotero 插件